If the Food and Drug Administration approves nirsevimab, it will be the first medical intervention available in the U.S. that can protect infants from RSV.
from U.S. News https://www.cnbc.com/2023/06/08/fda-advisors-recommend-astrazeneca-antibody-for-infants-for-rsv.html
No comments:
Post a Comment